South San Francisco, CA- and Cambridge, MA-based early-stage life sciences venture capital firm MPM Capital has appointed Chris Varma, PhD, as Entrepreneur-in-Residence.
In this role, Varma will primarily be responsible for advancing MPM’s oncology company creation activities. An experienced entrepreneur and investor in the industry, he has held leadership roles at multiple early-stage, venture-backed biomedical startup companies.
As co-founder of Blueprint Medicines (Nasdaq: BPMC), an oncology therapeutics company, he served as its President and Chief Executive Officer and was responsible for developing its platform, recruiting leadership and scientific teams, raising a $40M Series-A financing, and building its therapeutic pipeline ─ now in clinical testing.
Most recently, Varma co-founded and served as President and Chief Executive Officer of Vision Medicines, Inc., an orphan ophthalmology company.
He currently serves as a member of the Harvard Medical School (HMS) Therapeutics Advisory Council and the HMS Discovery Council, and is also a leadership board member of The McGovern Institute for Brain Research at MIT and a member of the board of directors of the Global Oncology Initiative (GO).
Led by Ansbert Gadicke, co-founder and Managing Director, MPM is founding and investing in companies that seek to innovate across multiple areas including cancer, diabetes, obesity, pain, eHealth and more.
FinSMEs
09/02/2017